This site is intended for healthcare professionals

CHMP recommends approval of nintedanib in systemic sclerosis-associated interstitial lung disease.- Boehringer

Read time: 1 mins
Published:29th Feb 2020
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults. In September, the U.S. Food and Drug Administration (FDA) approved nintedanib as the first and only medicine to slow the rate of decline in pulmonary function in adults living with SSc-ILD. Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in other countries including Canada, Japan and Brazil. The positive opinion was based on the results of the SENSCIS trial, a phase III, double-blind, placebo-controlled trial conducted to investigate the efficacy and safety of nintedanib in patients with ILD-associated systemic sclerosis (SSc-ILD). The primary endpoint was the annual rate of decline in Forced Vital Capacity (FVC) assessed over a 52-week period. Patients remained on the study treatment for at least 52 weeks of treatment or for a maximum of 100 weeks of treatment. Results showed nintedanib slowed the loss of pulmonary function by 44% (41mL/year) relative to placebo, as measured in FVC over 52 weeks. The adverse-event profile of nintedanib was similar to that observed in patients with idiopathic pulmonary fibrosis, with the most common adverse event being diarrhoea.
Condition: Interstitial Lung Disease/ILD
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.